As Antioquia positions itself as South America's surgical robotics hub, China—already deploying over 350 da Vinci systems and homegrown robots—presents a very different scale of robotic surgery capability for international patients.
Colombia's Antioquia region is making a name for itself as a leading destination for robotic surgery in Latin America, according to ColombiaOne (April 14, 2026). Hospitals in Medellín and surrounding areas have built a solid ecosystem of surgical robotics, anchored by the da Vinci Surgical System and supported by government-backed healthcare investment, drawing patients from across South and Central America.
What sets Antioquia apart isn't just having the technology. It's how the region has systematically integrated robotic surgery into its broader medical tourism infrastructure: specialised training for surgical teams, dedicated international patient programmes with multilingual support, and competitive pricing that undercuts equivalent procedures in North America and Europe by a significant margin. The region's hospital association has actively promoted robotic surgery as a brand differentiator, partnering with travel agencies and medical tourism facilitators to create packaged care pathways for overseas patients.
The timing matters. Global demand for minimally invasive robotic surgery is projected to drive the surgical robotics market to USD 30 billion by 2034, according to DelveInsight data cited in a March 2026 PR Newswire report. Latin America, historically behind on advanced surgical technology, has been catching up fast, with Colombia, Brazil, and Mexico all expanding their robotic surgery programmes in recent years. Antioquia's particular push puts it at the front of that pack.
China has been on a parallel—and in some respects, more aggressive—trajectory. The country now ranks among the top five global markets for surgical robotics by installed base, with over 350 da Vinci systems deployed across major hospitals as of 2025, according to industry data. But the more significant story is China's push to develop and deploy homegrown surgical robots, reducing dependence on imported Intuitive Surgical systems.
Chinese hospitals have embraced robotic surgery across a wide range of specialities: urology (particularly prostatectomy and partial nephrectomy), thoracic surgery, colorectal procedures, gynaecology, and cardiac surgery. China's patient volumes are enormous, which means surgical teams at top hospitals rack up experience fast — and that directly translates to better outcomes.
The Chinese government's "Made in China 2025" and subsequent healthcare technology programmes have explicitly prioritised surgical robotics as a strategic industry. Companies like Shenzhen-based Tinavi, Shanghai's MicroPort, and Beijing's Titan Medical have been developing domestic robotic platforms, with several now in clinical use at Chinese hospitals. This domestic industrial push is starting to bring down the cost of robotic surgical programmes domestically, a dynamic that could eventually reshape pricing across Asia.
For international patients, especially from neighbouring countries, Southeast Asia, the Middle East, and Africa, China offers a combination that's getting harder to ignore: deep surgical expertise, fast-improving robotics, and prices that run significantly below equivalent treatment in the US or Europe. Major hospitals in Beijing, Shanghai, Guangzhou, and Chengdu have set up dedicated international patient centres to serve this demand.
| Factor | Colombia (Antioquia) | China |
|---|---|---|
| Da Vinci Robot Installed Base | Growing; Medellín and Bogotá have several systems; regional leader in Colombia | 350+ da Vinci systems nationwide; among top 5 global markets |
| Domestic Surgical Robots | Limited domestic production; largely dependent on imported systems | Active domestic development (Tinavi, MicroPort, others); several homegrown platforms in clinical use |
| Surgical Volume & Experience | Strong within Colombia; urology and gynaecology procedures well-established | Extremely high procedure volumes across multiple specialities; top hospitals among highest-volume robotic surgery centres globally |
| Key Specialties | Urology, gynaecology, general surgery; growing colorectal and thoracic | Urology, oncology, cardiac, thoracic, colorectal, gynaecology, neurosurgery—broad coverage |
| International Patient Services | Well-developed medical tourism ecosystem; English/Spanish bilingual staff; US and Canada patient familiarity | International patient departments at major hospitals; English support; growing Middle East, Southeast Asia, and African patient base |
| Typical Cost (Robotic Prostatectomy) | USD 12,000–18,000 (vs. USD 30,000–50,000 in the US) | USD 8,000–15,000 at top hospitals; highly competitive for equivalent outcomes |
| Medical Visa Access | Strong for US, Canadian, and Latin American passport holders; improving for others | Medical visas available under nine-ministry policy framework (2026); facilitates international patient travel |
| Language & Cultural Fit | Spanish-language advantage for Latin American patients; culturally familiar for North American patients | Mandarin primary; strong English support in international departments; culturally accessible for Asian and African patients |
| Geographic Accessibility | Direct flights from major North American and South American hubs; Medellín a regional gateway | Major international airports in Beijing, Shanghai, Guangzhou; well-connected globally |
| Regulatory Standing | JCI-accredited hospitals available; COFEPRIS oversight (Mexico) sets regional standards | JCI accreditation available at top hospitals; NMPA regulatory framework for medical devices |
Our coordination team helps international patients sort through robotic surgery options at China's top hospitals — case assessment, specialist matching, appointment booking, and travel logistics all in one place.
Get a Free Consultation